MENU
Aim higher

PREVAlL

Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer

The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). A range of preclinical safety and efficacy experiments will be performed to nominate a clinical candidate from a recently discovered and highly potent series of ERRa inhibitors. The new candidate drug will be supported by strong safety and efficacy data packages and be ready for clinical trials within 18 months after completion of the project.
Acronym: 
PREVAlL
Project ID: 
11 590
Ranking: 
5
Cut-off: 
7
Start date: 
01-03-2018
Project Duration: 
36months
Project costs: 
3 645 440.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Drug delivery and other equipment (including kidney dialysis machines)